Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03008616 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia
A Phase 2 study, sponsored by AMAG Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT03008616 is a Phase 2 study that was terminated before completion, run by AMAG Pharmaceuticals. The registered enrollment target is 58 participants.
The verdict
NCT03008616, a Phase 2 study, was terminated before completion, sponsored by AMAG Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This study evaluates the use of AMAG-423 (Digoxin Immune Fab) in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.
Interventions
- OTHER Placebo
- BIOLOGICAL AMAG-423 (digoxin immune fab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2017-04-12 |
| Est. Completion | 2020-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03008616
The ClinicalTrials.gov registry entry for NCT03008616 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AMAG Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03008616 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03008616 about?
NCT03008616 is a clinical study titled "Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia". This study evaluates the use of AMAG-423 (Digoxin Immune Fab) in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.
What is the current status of trial NCT03008616?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2017-04-12. Estimated completion is 2020-08-13.
What interventions are being tested in trial NCT03008616?
The interventions under investigation include: Placebo (OTHER), AMAG-423 (digoxin immune fab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03008616?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.